Central Neurocytoma Diagnosis and Treatment Strategies

Central neurocytoma is a rare neuronal neoplasm arising typically within the lateral ventricles of the brain, predominantly affecting young adults. Diagnosis relies on a combination of advanced imaging techniques, histopathological evaluation and increasingly, molecular profiling. Magnetic resonance imaging often reveals well-demarcated intraventricular masses with heterogeneous enhancement, calcifications and cystic change. Definitive diagnosis requires tissue sampling, with histology showing uniform small round cells with neuronal differentiation and synaptophysin positivity. Ki-67 labelling index guides classification into typical or atypical variants, the latter carrying a higher risk of recurrence. The mainstay of treatment is maximal safe surgical resection, with gross total resection offering the best long-term outcomes. In cases of residual tumour or atypical histology, adjuvant radiotherapy or stereotactic radiosurgery can prolong progression-free intervals while maintaining acceptable toxicity profiles. Recent advances in molecular diagnostics, particularly methylation profiling, have refined diagnostic accuracy and may inform risk stratification. Multidisciplinary management incorporating neurosurgery, neuroradiology and neuro-oncology is essential to tailor interventions, optimise survival and preserve neurological function. Close imaging surveillance is critical owing to the potential for late recurrence or dissemination, especially in atypical cases. Emerging strategies focus on integrating molecular biomarkers with conventional treatment to enhance precision medicine approaches and improve functional outcomes for patients worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Central Neurocytoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in central neurocytoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Gross total resection (GTR): Surgical removal of all visible tumour tissue.

Subtotal resection (STR): Surgical removal leaving residual tumour in situ.

Progression-free survival (PFS): Time interval during which a tumour shows no signs of growth or recurrence.

Overall survival (OS): Duration from diagnosis or treatment start until death from any cause.

Methylation profiling: Molecular technique analysing DNA methylation patterns to classify tumours.

Ki-67 labelling index: Percentage of tumour cells expressing the proliferation marker Ki-67, indicating growth rate.

References

1. Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma. Radiation Oncology (2014).
2. Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis. Cancers (2021).
3. Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature. BMC Cancer (2020).
4. Clinical Outcomes and Prognostic Analysis of 101 Patients of Central Neurocytoma: A 10-Year Treatment Experience at a Single Institution. Frontiers in Oncology (2022).
5. Atypical Central Neurocytoma with Recurrent Spinal Dissemination over a Period of 20 Years: A Case Report and Review of the Literature. Case Reports in Neurological Medicine (2013).
6. The role of methylation profiling in histologically diagnosed neurocytoma: a case series. Journal of Neuro-Oncology (2022).
7. Atypical Neurocytoma: Dilemma in diagnosis and management. Surgical Neurology International (2014).